150 related articles for article (PubMed ID: 31982207)
1. Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
Klos D; Riško J; Kriváčková D; Loveček M; Skalický P; Neoral Č; Melichar B; Mohelníková-Duchoňová B; Lemstrová R
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):607-612. PubMed ID: 31982207
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
3. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.
Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA
Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258
[TBL] [Abstract][Full Text] [Related]
4. Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application.
McBride KE; Steffens D; Solomon MJ; Koh C; Ansari N; Young CJ; Moran B
Eur J Surg Oncol; 2021 Apr; 47(4):828-833. PubMed ID: 32972815
[TBL] [Abstract][Full Text] [Related]
5. Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases.
Simkens GA; Rovers KP; van Oudheusden TR; Nienhuijs SW; Rutten HJ; de Hingh IH
Medicine (Baltimore); 2018 Mar; 97(10):e0042. PubMed ID: 29517660
[TBL] [Abstract][Full Text] [Related]
6. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability.
Bagnoli PF; Cananzi FC; Brocchi A; Ardito A; Strada D; Cozzaglio L; Mussi C; Brusa S; Carlino C; Borrelli B; Alemanno F; Quagliuolo V
Eur J Surg Oncol; 2015 Mar; 41(3):386-91. PubMed ID: 25554680
[TBL] [Abstract][Full Text] [Related]
7. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
8. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
9. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience.
Vukadinovic V; Chiou JD; Morris DL
Eur J Surg Oncol; 2015 May; 41(5):702-6. PubMed ID: 25680953
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.
Choudry MHA; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Dec; 25(13):3950-3959. PubMed ID: 30302637
[TBL] [Abstract][Full Text] [Related]
13. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
14. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
[TBL] [Abstract][Full Text] [Related]
16. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
17. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
Schneider MA; Eshmuminov D; Lehmann K
Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Enhanced Recovery After Following a Surgical Protocol for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
Duzgun O
Med Arch; 2019 Oct; 73(5):331-337. PubMed ID: 31819307
[TBL] [Abstract][Full Text] [Related]
20. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]